IP Library › Granted Patent US 12,285,251
Granted Patent B2
US 12,285,251 · App. 17/543,633 · Granted Apr 29, 2025

Systems, devices, and methods related to the individualized calibration and/or manufacturing of medical devices

Inventors: Steven Scott (Pleasanton, CA); Christopher J. Bennell (Carterton, GB); Claire Bhogal (Witney, GB); Katie A. Cranfield (Reading, GB); Marc B. Taub (Oxford, GB); Bree M. Winter (Witney, GB); Owen D. Reynolds (Cricklade, GB); Jean-Pierre Babka (Alameda, CA); Dharmendra S. Patel (Stanton Harcourt, GB); Christopher A. Thomas (Cheltenham, GB); Udo Hoss (Castro Valley, CA); Mark S. Yahnke (Alameda, CA); Tahir S. Khan (Fremont, CA)
Assignee: ABBOTT DIABETES CARE INC.
A61B5/1495A61B5/14503A61B5/14532A61B5/14546A61B5/0002A61B2560/0223A61B2562/12A61M1/1603
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,285,251
App. No.
17/543,633
Granted
Apr 29, 2025
Kind
B2
Abstract

Systems, devices, kits, and methods are provided herein in the form of example embodiments that relate to calibration of medical devices. The medical devices can be sensors adapted to sense a biochemical attribute. The embodiments can be used to determine calibration information specific to an individual medical device. The embodiments can determine the calibration information by reference to one or more parameters obtained during manufacturing of the medical device. The embodiments can also determine the calibration information by reference to in vitro testing of the medical devices. The embodiments also apply to systems incorporating those medical devices in their use in the field. Also described are embodiments of modifications to surfaces of sensor substrates, such as through applied radiation and/or the creation of a well, to aid in the placement and/or sizing of a sensor element on the substrate.

Claims (42)

1. A continuous glucose monitoring system, comprising:

an in vivo sensor configured to generate a signal associated with a glucose level, wherein a first portion of the in vivo sensor is configured to be positioned beneath a skin surface of a user in the subcutaneous space and a second portion of the in vivo sensor is configured to remain outside the user; and

an on-skin sensor control unit, wherein the in vivo sensor is coupled to the sensor control unit and wherein the sensor control unit is programmed to process the generated signal from the in vivo sensor to generate a processed result that is representative of a glucose level of the user using calibration information, wherein the calibration information comprises a sensing characteristic of the in vivo sensor, and wherein the sensing characteristic is determined based at least in part on f 1 (RMP A ) and f 2 (RMP B );

wherein f 1 is a first nonlinear function of RMP A , and f 2 is a second nonlinear function of RMP B ; and

wherein RMP A is a first manufacturing parameter, and RMP B is a second manufacturing parameter.

2. The continuous glucose monitoring system of claim 1 , wherein the first manufacturing parameter affects a sensitivity of the in vivo sensor and the second manufacturing parameter affects the sensitivity of the in vivo sensor.

3. The continuous glucose monitoring system of claim 1 , wherein the in vivo sensor comprises a sensing region and the first manufacturing parameter comprises a size of the sensing region.

4. The continuous glucose monitoring system of claim 3 , wherein the size of the sensing region is representative of a width of the sensing region.

5. The continuous glucose monitoring system of claim 3 , wherein the size of the sensing region is representative of a length of the sensing region.

6. The continuous glucose monitoring system of claim 3 , wherein the size of the sensing region is representative of a thickness of the sensing region.

7. The continuous glucose monitoring system of claim 3 , wherein the size of the sensing region is representative of a peripheral length of the sensing region.

8. The continuous glucose monitoring system of claim 3 , wherein the size of the sensing region is representative of a volume of the sensing region.

9. The continuous glucose monitoring system of claim 1 , wherein the in vivo sensor is non-planar and comprises a working electrode and a counter electrode separated by non-conductive material.

10. The continuous glucose monitoring system of claim 1 , wherein the in vivo sensor comprises an analyte flux modulating membrane adjacent a sensing region.

11. The continuous glucose monitoring system of claim 10 , wherein the membrane is a non-planar membrane.

12. The continuous glucose monitoring system of claim 10 , wherein the first manufacturing parameter comprises a size of the membrane.

13. The continuous glucose monitoring system of claim 12 , wherein the size of the membrane is representative of a thickness of the membrane.

14. The continuous glucose monitoring system of claim 1 , wherein the first manufacturing parameter is an individualized manufacturing parameter.

15. The continuous glucose monitoring system of claim 14 , wherein the second manufacturing parameter is an individualized manufacturing parameter.

16. The continuous glucose monitoring system of claim 14 , wherein the in vivo sensor is manufactured concurrently with a batch of other in vivo sensors, and the second manufacturing parameter is the same for each in vivo sensor in the batch.

17. The continuous glucose monitoring system of claim 1 , wherein the in vivo sensor is manufactured concurrently with a batch of other in vivo sensors, and the first manufacturing parameter is the same for each in vivo sensor in the batch.

18. The continuous glucose monitoring system of claim 17 , wherein the second manufacturing parameter is an individualized manufacturing parameter.

19. The continuous glucose monitoring system of claim 17 , wherein the second manufacturing parameter is the same for each in vivo sensor in the batch.

20. The continuous glucose monitoring system of claim 1 , wherein the glucose monitoring system is configured for factory calibration such that it does not require user calibration or automated system calibration based on a reference value provided to the glucose monitoring system.

21. The continuous glucose monitoring system of claim 1 , wherein the glucose monitoring system is configured for user calibration.

22. The continuous glucose monitoring system of claim 1 , f 1 includes a first coefficient.

23. The continuous glucose monitoring system of claim 22 , wherein the first coefficient is empirically determined.

24. The continuous glucose monitoring system of claim 22 , wherein the in vivo sensor is manufactured concurrently with a batch of other in vivo sensors, and the first coefficient is the same for each in vivo sensor in the batch.

25. The continuous glucose monitoring system of claim 22 , wherein the first coefficient is determined for the in vivo sensor on an individual basis.

26. The continuous glucose monitoring system of claim 22 , wherein f 2 includes a second coefficient.

27. The continuous glucose monitoring system of claim 26 , wherein the in vivo sensor is manufactured concurrently with a batch of other in vivo sensors, and the second coefficient is the same for each in vivo sensor in the batch.

28. The continuous glucose monitoring system of claim 26 , wherein the second coefficient is determined for the in vivo sensor on an individual basis.

29. The continuous glucose monitoring system of claim 1 , wherein the sensing characteristic is further determined base at least in part on f 3 (RMP c ), where f 3 is a third nonlinear function, and RMP C is a third manufacturing parameter.

30. The continuous glucose monitoring system of claim 1 , wherein the in vivo sensor comprising a sensing region comprising a sensing element, the sensing element being on a modified area of a sensor substrate having a liquid mobility characteristic different than an adjacent area of the sensor substrate.

31. A continuous glucose monitoring system, comprising:

an in vivo sensor configured to generate a signal associated with a glucose level of a user, the sensor including

a first portion configured to be positioned beneath a skin surface of the user and including a working electrode and a counter electrode,

a second portion configured to remain outside the user and including a first contact electrically coupled to the working electrode and a second contact electrically coupled to the counter electrode, and

at least one interferent-eliminating membrane layer disposed over the working electrode; and

a sensor control unit, wherein the first contact and the second contact of the in vivo sensor are each electrically coupled to the sensor control unit, and wherein the sensor control unit is programmed to process the generated signal from the in vivo sensor to generate a processed result that is representative of a glucose level of the user using calibration information, wherein the calibration information comprises a sensing characteristic of the in vivo sensor, and wherein the sensing characteristic is determined based at least in part on f 1 (RMP A ) and f 2 (RMP B );

wherein f 1 is a first nonlinear function of RMP A , and f 2 is a second nonlinear function of RMP B ; and

wherein RMP A is a first manufacturing parameter, and RMP B is a second manufacturing parameter.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2021
From: REYNOLDS, OWEN D.; BABKA, JEAN-PIERRE; PATEL, DHARMENDRA S.; THOMAS, CHRISTOPHER A.; HOSS, UDO; YAHNKE, MARK S.; KHAN, TAHIR S.
To: ABBOTT DIABETES CARE INC.
Reel/Frame 058337/0513 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2021
From: SCOTT, STEVEN; BENNELL, CHRISTOPHER J.; BHOGAL, CLAIRE; CRANFIELD, KATIE A.; TAUB, MARC B.; WINTER, BREE M.
To: ABBOTT DIABETES CARE INC.
Reel/Frame 058393/0468 →
Continuity (4)
Continuation 17306833 · May 3, 2021
Continuation 15999212 · Aug 17, 2018
Provisional Application 62547635 · Aug 18, 2017
Related Publication 20220087576A1 · Mar 24, 2022
References Cited (400)
US 2892990A · Werndl · 1959 [cited by applicant]
US 4639062A · Taniguchi et al. · 1987 [cited by applicant]
US 4650547A · Gough · 1987 [cited by applicant]
US 4703756A · Gough et al. · 1987 [cited by applicant]
US 4750496A · Reinhart et al. · 1988 [cited by applicant]
US 5034112A · Murase et al. · 1991 [cited by applicant]
US 5089112A · Skotheim et al. · 1992 [cited by applicant]
US 5145381A · Volz · 1992 [cited by applicant]
US 5262035A · Gregg et al. · 1993 [cited by applicant]
US 5262305A · Heller et al. · 1993 [cited by applicant]
US 5264103A · Yoshioka et al. · 1993 [cited by applicant]
US 5264104A · Gregg et al. · 1993 [cited by applicant]
US 5320715A · Berg · 1994 [cited by applicant]
US 5352351A · White et al. · 1994 [cited by applicant]
US 5391250A · Cheney, II et al. · 1995 [cited by applicant]
US 5411647A · Johnson et al. · 1995 [cited by applicant]
US 5482473A · Lord et al. · 1996 [cited by applicant]
US 5497772A · Schulman et al. · 1996 [cited by applicant]
US 5591137A · Stevens · 1997 [cited by applicant]
US 5593852A · Heller et al. · 1997 [cited by applicant]
US 5695623A · Michel et al. · 1997 [cited by applicant]
US 5700360A · Chan et al. · 1997 [cited by applicant]
US 5786439A · Van Antwerp et al. · 1998 [cited by applicant]
US 5791344A · Schulman et al. · 1998 [cited by applicant]
US 5863400A · Drummond et al. · 1999 [cited by applicant]
US 6001067A · Shults et al. · 1999 [cited by applicant]
US 6096268A · Inbar · 2000 [cited by applicant]
US 6103033A · Say et al. · 2000 [cited by applicant]
US 6168957B1 · Matzinger et al. · 2001 [cited by applicant]
US 6175752B1 · Say et al. · 2001 [cited by applicant]
US 6180221B1 · Crotzer et al. · 2001 [cited by applicant]
US 6203354B1 · Kuwahara et al. · 2001 [cited by applicant]
US 6212417B1 · Ikeda et al. · 2001 [cited by applicant]
US 6232609B1 · Snyder et al. · 2001 [cited by applicant]
US 6237394B1 · Harris et al. · 2001 [cited by applicant]
US 6275717B1 · Gross et al. · 2001 [cited by applicant]
US 6284478B1 · Heller et al. · 2001 [cited by applicant]
US 6360888B1 · McIvor et al. · 2002 [cited by applicant]
US 6366794B1 · Moussy et al. · 2002 [cited by applicant]
US 6368141B1 · VanAntwerp et al. · 2002 [cited by applicant]
US 6377894B1 · Deweese et al. · 2002 [cited by applicant]
US 6424847B1 · Mastrototaro et al. · 2002 [cited by applicant]
US 6475372B1 · Ohara et al. · 2002 [cited by applicant]
US 6475750B1 · Han et al. · 2002 [cited by applicant]
US 6522903B1 · Berman et al. · 2003 [cited by applicant]
US 6558321B1 · Burd et al. · 2003 [cited by applicant]
US 6560471B1 · Heller et al. · 2003 [cited by applicant]
US 6565509B1 · Say et al. · 2003 [cited by applicant]
US 6587704B1 · Fine et al. · 2003 [cited by applicant]
US 6616819B1 · Liamos et al. · 2003 [cited by applicant]
US 6618934B1 · Feldman et al. · 2003 [cited by applicant]
US 6650471B2 · Doi · 2003 [cited by applicant]
US 6676600B1 · Conero · 2004 [cited by applicant]
US 6736957B1 · Forrow et al. · 2004 [cited by applicant]
US 6746582B2 · Heller et al. · 2004 [cited by applicant]
US 6809653B1 · Mann et al. · 2004 [cited by applicant]
US 6835553B2 · Han et al. · 2004 [cited by applicant]
US 6850859B1 · Schuh · 2005 [cited by applicant]
US 6931327B2 · Goode, Jr. et al. · 2005 [cited by applicant]
US 6990366B2 · Say et al. · 2006 [cited by applicant]
US 7220387B2 · Flaherty et al. · 2007 [cited by applicant]
US 7299082B2 · Feldman et al. · 2007 [cited by applicant]
US 7418285B2 · Ghesquiere et al. · 2008 [cited by applicant]
US 7491303B2 · Sakata et al. · 2009 [cited by applicant]
US 7501053B2 · Karinka et al. · 2009 [cited by applicant]
US 7525315B2 · Fredette et al. · 2009 [cited by applicant]
US 7545272B2 · Goodnow et al. · 2009 [cited by applicant]
US 7749740B2 · Eiteman et al. · 2010 [cited by applicant]
US 7754093B2 · Forrow et al. · 2010 [cited by applicant]
US 7811231B2 · Jin et al. · 2010 [cited by applicant]
US 7866026B1 · Wang et al. · 2011 [cited by applicant]
US 8083928B2 · Feldman et al. · 2011 [cited by applicant]
US 8115635B2 · Goodnow et al. · 2012 [cited by applicant]
US 8236166B2 · Karinka et al. · 2012 [cited by applicant]
US 8260556B2 · Likuski et al. · 2012 [cited by applicant]
US 8297128B2 · Delbos et al. · 2012 [cited by applicant]
US 8396670B2 · St-Pierre · 2013 [cited by applicant]
US 8497777B2 · Harper · 2013 [cited by applicant]
US 8583205B2 · Budiman et al. · 2013 [cited by applicant]
US 8771183B2 · Sloan · 2014 [cited by applicant]
US 8828330B2 · Galasso et al. · 2014 [cited by applicant]
US 9241631B2 · Valdes et al. · 2016 [cited by applicant]
US 9504471B2 · Vaitekunas et al. · 2016 [cited by applicant]
US 9538943B1 · Cross et al. · 2017 [cited by applicant]
US 9782112B2 · Moein et al. · 2017 [cited by applicant]
US 9801577B2 · Budiman et al. · 2017 [cited by applicant]
US 9808574B2 · Yodfat et al. · 2017 [cited by applicant]
US 10709364B2 · Kamath et al. · 2020 [cited by applicant]
US 10820842B2 · Harper · 2020 [cited by applicant]
US 10827954B2 · Hoss et al. · 2020 [cited by applicant]
US 10874338B2 · Stafford · 2020 [cited by applicant]
US 10881341B1 · Curry et al. · 2021 [cited by applicant]
US 10945647B2 · Mazza et al. · 2021 [cited by applicant]
US 10945649B2 · Lee et al. · 2021 [cited by applicant]
US 10952653B2 · Harper · 2021 [cited by applicant]
US 10959654B2 · Curry et al. · 2021 [cited by applicant]
US 10966644B2 · Stafford · 2021 [cited by applicant]
US 10973443B2 · Funderburk et al. · 2021 [cited by applicant]
US 11000213B2 · Kamath et al. · 2021 [cited by applicant]
US 11000216B2 · Curry et al. · 2021 [cited by applicant]
US 11013440B2 · Lee et al. · 2021 [cited by applicant]
US 11020031B1 · Simpson et al. · 2021 [cited by applicant]
US 11141084B2 · Funderburk et al. · 2021 [cited by applicant]
US 20020010390A1 · Guice et al. · 2002 [cited by applicant]
US 20020043651A1 · Darrow et al. · 2002 [cited by applicant]
US 20020161288A1 · Shin et al. · 2002 [cited by applicant]
US 20020177764A1 · Sohrab · 2002 [cited by applicant]
US 20030003524A1 · Taniike et al. · 2003 [cited by applicant]
US 20030065536A1 · Hansen et al. · 2003 [cited by applicant]
US 20030076082A1 · Morgan et al. · 2003 [cited by applicant]
US 20040018486A1 · Dunn et al. · 2004 [cited by applicant]
US 20040022438A1 · Hibbard · 2004 [cited by applicant]
US 20040106858A1 · Say et al. · 2004 [cited by applicant]
US 20040106860A1 · Say et al. · 2004 [cited by applicant]
US 20040118704A1 · Wang et al. · 2004 [cited by applicant]
US 20040122353A1 · Shahmirian et al. · 2004 [cited by applicant]
US 20040127777A1 · Ruchti et al. · 2004 [cited by applicant]
US 20040133164A1 · Funderburk et al. · 2004 [cited by applicant]
US 20040244151A1 · Sakata et al. · 2004 [cited by applicant]
US 20050004439A1 · Shin et al. · 2005 [cited by applicant]
US 20050027180A1 · Goode, Jr. et al. · 2005 [cited by applicant]
US 20050027463A1 · Goode, Jr. et al. · 2005 [cited by applicant]
US 20050043598A1 · Goode, Jr. et al. · 2005 [cited by applicant]
US 20050059871A1 · Gough et al. · 2005 [cited by applicant]
US 20050069892A1 · Iyengar et al. · 2005 [cited by applicant]
US 20050143636A1 · Zhang et al. · 2005 [cited by applicant]
US 20050151976A1 · Toma · 2005 [cited by applicant]
US 20050176136A1 · Burd et al. · 2005 [cited by applicant]
US 20050215871A1 · Feldman et al. · 2005 [cited by applicant]
US 20050239154A1 · Feldman et al. · 2005 [cited by applicant]
US 20050242479A1 · Petisce et al. · 2005 [cited by applicant]
US 20050245799A1 · Brauker et al. · 2005 [cited by applicant]
US 20060016700A1 · Brister et al. · 2006 [cited by applicant]
US 20060019327A1 · Brister et al. · 2006 [cited by applicant]
US 20060020187A1 · Brister et al. · 2006 [cited by applicant]
US 20060020188A1 · Kamath et al. · 2006 [cited by applicant]
US 20060020192A1 · Brister et al. · 2006 [cited by applicant]
US 20060025663A1 · Talbot et al. · 2006 [cited by applicant]
US 20060036143A1 · Brister et al. · 2006 [cited by applicant]
US 20060091006A1 · Wang et al. · 2006 [cited by applicant]
US 20060094944A1 · Chuang · 2006 [cited by applicant]
US 20060094945A1 · Barman et al. · 2006 [cited by applicant]
US 20060142651A1 · Brister et al. · 2006 [cited by applicant]
US 20060193375A1 · Lee · 2006 [cited by applicant]
US 20060222566A1 · Brauker · 2006 [cited by examiner]
US 20060258929A1 · Goode, Jr. et al. · 2006 [cited by applicant]
US 20060258959A1 · Sode · 2006 [cited by applicant]
US 20060276771A1 · Galley et al. · 2006 [cited by applicant]
US 20060281985A1 · Ward et al. · 2006 [cited by applicant]
US 20060293576A1 · Van Antwerp et al. · 2006 [cited by applicant]
US 20070237678A1 · Roesicke et al. · 2007 [cited by applicant]
US 20070249922A1 · Peyser et al. · 2007 [cited by applicant]
US 20070299617A1 · Willis · 2007 [cited by applicant]
US 20080066305A1 · Wang et al. · 2008 [cited by applicant]
US 20080172205A1 · Breton et al. · 2008 [cited by applicant]
US 20080234561A1 · Roesicke et al. · 2008 [cited by applicant]
US 20080267823A1 · Wang et al. · 2008 [cited by applicant]
US 20080278333A1 · Fennell et al. · 2008 [cited by applicant]
US 20080287761A1 · Hayter · 2008 [cited by examiner]
US 20080312842A1 · Hayter et al. · 2008 [cited by applicant]
US 20090006034A1 · Hayter et al. · 2009 [cited by applicant]
US 20090076360A1 · Brister et al. · 2009 [cited by applicant]
US 20090102678A1 · Mazza et al. · 2009 [cited by applicant]
US 20090108992A1 · Shafer · 2009 [cited by applicant]
US 20090143659A1 · Li et al. · 2009 [cited by applicant]
US 20090163789A1 · Say et al. · 2009 [cited by applicant]
US 20090178459A1 · Li et al. · 2009 [cited by applicant]
US 20090240120A1 · Mensinger et al. · 2009 [cited by applicant]
US 20090247857A1 · Harper et al. · 2009 [cited by applicant]
US 20100057042A1 · Hayter · 2010 [cited by applicant]
US 20100094111A1 · Heller et al. · 2010 [cited by applicant]
US 20100094112A1 · Heller et al. · 2010 [cited by applicant]
US 20100094610A1 · Matsuura · 2010 [cited by applicant]
US 20100145377A1 · Lai et al. · 2010 [cited by applicant]
US 20100198142A1 · Sloan et al. · 2010 [cited by applicant]
US 20100200538A1 · Petisce et al. · 2010 [cited by applicant]
US 20100230285A1 · Hoss et al. · 2010 [cited by applicant]
US 20100274515A1 · Hoss et al. · 2010 [cited by applicant]
US 20110120865A1 · Bommakanti · 2011 [cited by examiner]
US 20110124994A1 · Bommakanti · 2011 [cited by examiner]
US 20110178717A1 · Goodnow et al. · 2011 [cited by applicant]
US 20110213225A1 · Bernstein et al. · 2011 [cited by applicant]
US 20120150005A1 · Hoss et al. · 2012 [cited by applicant]
US 20120262298A1 · Bohm et al. · 2012 [cited by applicant]
US 20120265037A1 · Bohm et al. · 2012 [cited by applicant]
US 20120323098A1 · Moein et al. · 2012 [cited by applicant]
US 20140017709A1 · Lowe et al. · 2014 [cited by applicant]
US 20140060145A1 · Hoss et al. · 2014 [cited by applicant]
US 20140121480A1 · Budiman et al. · 2014 [cited by applicant]
US 20140200917A1 · Galasso et al. · 2014 [cited by applicant]
US 20140278189A1 · Vanslyke et al. · 2014 [cited by applicant]
US 20150005601A1 · Hoss et al. · 2015 [cited by applicant]
US 20160007890A1 · Kovatchev · 2016 [cited by examiner]
US 20170017512A1 · Garcia et al. · 2017 [cited by applicant]
US 20170074757A1 · Garcia et al. · 2017 [cited by applicant]
US 20170112531A1 · Schoonmaker et al. · 2017 [cited by applicant]
US 20170135618A1 · Brister et al. · 2017 [cited by applicant]
US 20170181681A1 · Boock et al. · 2017 [cited by applicant]
US 20170184527A1 · Nogueira et al. · 2017 [cited by applicant]
US 20170188906A1 · Ma et al. · 2017 [cited by applicant]
US 20170188907A1 · Ma et al. · 2017 [cited by applicant]
US 20170188908A1 · Hoss et al. · 2017 [cited by applicant]
US 20170196491A1 · Brister et al. · 2017 [cited by applicant]
US 20190274598A1 · Scott et al. · 2019 [cited by applicant]
EP 1391728 · 2004 [cited by applicant]
EP 1413879 · 2012 [cited by applicant]
EP 3575796 · 2019 [cited by applicant]
EP 3797682 · 2021 [cited by applicant]
EP 3831282 · 2022 [cited by applicant]
WO WO9816975A1 · 1998 [cited by applicant]
WO WO9958190A1 · 1999 [cited by applicant]
WO WO0049941 · 2000 [cited by applicant]
WO WO0117425A2 · 2001 [cited by applicant]
WO WO02058537 · 2002 [cited by applicant]
WO WO03012422 · 2003 [cited by applicant]
WO WO03032411 · 2003 [cited by applicant]
WO WO03094714 · 2003 [cited by applicant]
WO WO2005011489 · 2005 [cited by applicant]
WO WO2005026689 · 2005 [cited by applicant]
WO WO2005070287 · 2005 [cited by applicant]
WO WO2006026741 · 2006 [cited by applicant]
WO WO2006099151 · 2006 [cited by applicant]
WO WO2008021913 · 2008 [cited by applicant]
WO WO2008042918A2 · 2008 [cited by applicant]
WO WO2008143943A1 · 2008 [cited by applicant]
WO WO2010099507 · 2010 [cited by applicant]
WO WO2011011643 · 2011 [cited by applicant]
WO WO2012142502 · 2012 [cited by applicant]
WO WO2014105631 · 2014 [cited by applicant]
WO WO2014158327A2 · 2014 [cited by applicant]
WO WO2017044654A1 · 2017 [cited by applicant]
WO WO2017116503A1 · 2017 [cited by applicant]
WO WO2017117416A1 · 2017 [cited by applicant]
U.S. Appl. No. 15/999,212 (U.S. Pat. No. 10,993,646), filed Aug. 17, 2018 (May 4, 2021). [cited by applicant]
U.S. Appl. No. 17/306,833 (US 2021-0267500 A1), filed May 3, 2021 (Sep. 2, 2021). [cited by applicant]
U.S. Appl. No. 15/999,212, filed Mar. 18, 2021 Issue Fee Payment. [cited by applicant]
U.S. Appl. No. 15/999,212, filed Mar. 17, 2021 Notice of Allowance. [cited by applicant]
U.S. Appl. No. 15/999,212, filed Mar. 8, 2021 Response after Final Action. [cited by applicant]
U.S. Appl. No. 15/999,212, filed Jan. 6, 2021 Final Office Action. [cited by applicant]
U.S. Appl. No. 15/999,212, filed Dec. 3, 2020 Response to Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 15/999,212, filed Sep. 3, 2020 Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 17/306,833, filed Nov. 10, 2021 Corrected Notice of Allowability. [cited by applicant]
U.S. Appl. No. 17/306,833, filed Nov. 2, 2021 Issue Fee Payment. [cited by applicant]
U.S. Appl. No. 17/306,833, filed Oct. 28, 2021 Notice of Allowance. [cited by applicant]
U.S. Appl. No. 17/306,833, filed Oct. 15, 2021 Response to Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 17/306,833, filed Jul. 15, 2021 Non-Final Office Action. [cited by applicant]
Acciaroli et al., “Reduction of Blood Glucose Measurements to Calibrate Subcutaneous Glucose Sensors: A Bayesian Multiday Framework”, IEEE Transactions on Biomedical Engineering, vol. 65, No. 3, Mar. 2018, pp. 587-595. [cited by applicant]
Chen et al., “Current and Emerging Technology for Continuous Glucose Monitoring”, Sensors, 2017, vol. 17, pp. 182-200. [cited by applicant]
Hoss et al., “Factory-Calibrated Continuous Glucose Sensors: The Science Behind the Technology,” Diabetes Technology & Therapeutics, 2017, vol. 19, Supplement 2, pp. S44-S50. [cited by applicant]
Hoss et al., “Feasibility of Factory Calibration for Subcutaneous Glucose Sensors in Subjects with Diabetes,” Journal of Diabetes Science and Technology, 2014, vol. 8, No. 1, pp. 89-94. [cited by applicant]
McGarraugh, “The Chemistry of Commercial Continuous Glucose Monitors,” Diabetes Technology & Therapeutics, 2009, vol. 11, Supplement 1, pp. S17-S24. [cited by applicant]
WO PCT/IB2018/056223 Invitation to Pay Additional Fees dated Jan. 10, 2019. [cited by applicant]
WO PCT/IB2018/056223 ISR and Written Opinion dated May 20, 2019. [cited by applicant]
Examiner's Report dated May 26, 2022 in corresponding Canadian Patent Application No. 3,065,746. [cited by applicant]
U.S. Appl. No. 60/606,334, filed Aug. 31, 2004, Griffith, et al. [cited by applicant]
“Abbott's Continuous Blood Glucose Monitor Approval Soon” retrieved from https://www.diabetesincontrol.com/abbotts-continuous-blood-glucose-monitor-approval-soon/, Oct. 3, 2006, 3 pages. [cited by applicant]
“Children with Diabetes, Report from Diabetes Technology Meeting” retrieved from https://archive.childrenwithdiabetes.com/d_0j_129.htm on Jan. 21, 2022, 3 pages. [cited by applicant]
“In Vivo Glucose Sensing”, Chemical Analysis, A Series of Monographs on Analytical Chemistry and its Applications, vol. 174, 466 pages (2010). [cited by applicant]
“Leading the Way for You and Your Patients with Continuous Glucose Monitoring” Brochure, Dexcom Inc., 12 pages (2010). [cited by applicant]
“TheraSense Files Premarket Approval Application for Freestyle Navigator(TM) Cont” retrieved from https:www.diabetesincontrol.com/therasense-files-premarket-approval-application-for-freestyle-navigatortm-cont/, Dec. 13,… [cited by applicant]
“Therasense Navigates Continuous Glucose Monitor PMA, Prepares for Flash”, The Gray Sheet, 29(37):18 (2003). [cited by applicant]
“U.S. Food & Drug Administration, Premarket Approval (PMA) for Freestyle Navigator Continuous Glucose Monitor” retrieved from https:www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P050020 on Jan. 23, 2022, 6… [cited by applicant]
Bard, et al., Electrochemical Methods, Fundamentals and Applications, pp. 174-175 (1980). [cited by applicant]
Chen, et al., “Defining the Period of Recovery of the Glucose Concentration after Its Local Perturbation by the Implantation of a Miniature Sensor”, Clin Chem Lab Med, 40(8):786-789 (2002). [cited by applicant]
Chen, et al., “Glucose microbiosensor based on alumina sol gel matrix/eletropolymerized composite membrane”, Biosensors and Bioelectronics, 17:1005-1013 (2002). [cited by applicant]
Chen, et al., “In Situ Assembled Mass-Transport Controlling Micromembranes and Their Application in Implanted Amperometric Glucose Sensors”, Analytical Chemistry, 72(16):3757-3763 (2000). [cited by applicant]
Chen, et al., “In vivo Glucose Monitoring with Miniature “Wired” Glucose Oxidase Electrodes”, Analytical Sciences, 17:i297-i300 (2001). [cited by applicant]
Choleau, et al., “Calibration of a subcutaneous amperometric glucose sensor Part 1. Effect of measurement uncertainties on the determination of sensor sensitivity and background current”, Biosensors and Bioelectronics, … [cited by applicant]
Chung, “In vitro Evaluation of the Continuous Monitoring Glucose Sensors with Perfluorinated Tetrafluoroethylene Coatings”, Bull. Korean Chem. Soc., 24(4):514-516 (2003). [cited by applicant]
Csöregi, et al., “Design, Characterization, and One-Point in Vivo Calibration of a Subcutaneously Implanted Glucose Electrode”, Anal. Chem., 66(19):3131-3138 (1994). [cited by applicant]
Determination of Regulatory Review Period for Purposes of Patent Extension; SEVENFACT, Department of Health and Human Services, Food and Drug Administration, Notice, Federal Register, 86(211):60827-60829 (2021). [cited by applicant]
Diabetes Close Up, Conferences #2, Diabetes Technology—DAWN Summit, https://www.closeconcerns.com/, pp. 1-8, (2003). [cited by applicant]
Feldman, et al., “A Continuous Glucose Sensor Based on Wired Enzyme™ Technology—Results from a 3-Day Trial in Patients with Type 1 Diabetes”, Diabetes Technology & Therapeutics, 5(5):769-779 (2003). [cited by applicant]
Fischer, “Fundamentals of Glucose Sensors”, Diabetic Medicine, 8:309-321 (1991). [cited by applicant]
FreeStyle Navigator Continuous Glucose Monitoring System, Summary of Safety and Effectiveness Data in support of Pre-Market Approval (PMA) No. P050020, Abbott Diabetes Care, 27 pages (2008). [cited by applicant]
FreeStyle Navigator Continuous Glucose Monitoring System, User Guide, Abbott Diabetes Care Inc., 195 pages (2008). [cited by applicant]
FreeStyle Navigator Continuous Monitoring System, User's Guide, Abbott Diabetes Care Inc., 38 pages, (2008). [cited by applicant]
Gerritsen, et al., “Performance of subcutaneously implanted glucose sensors for continuous monitoring”, The Netherlands Journal of Medicine, 54:167-179 (1999). [cited by applicant]
Guardian® REAL-Time, Continuous Glucose Monitoring System, User Guide, Medtronic MiniMed, Inc., 181 pages (2006). [cited by applicant]
Guardian® RT, Continuous Glucose Monitoring System, REF MMT-7900, User Guide, Medtronic MiniMed, 128 pages (2005). [cited by applicant]
Heise, et al., “Hypoglycemia Warning Signal and Glucose Sensors: Requirements and Concepts”, Diabetes Technology & Therapeutics, 5(4):563-571 (2003). [cited by applicant]
Heller, “Implanted Electrochemical Glucose Sensors for the Management of Diabetes”, Annu. Rev. Biomed. Eng., 01:153-175 (1999). [cited by applicant]
Heller, “Integrated Medical Feedback Systems for Drug Delivery”, AIChE Journal, 51(4):1054-1066 (2005). [cited by applicant]
Heller, et al., “Electrochemical Glucose Sensors and Their Applications in Diabetes Management”, Chemical Reviews, 108(7):2482-2505 (2008). [cited by applicant]
Heller, et al., “Electrochemistry in Diabetes Management”, Accounts of Chemical Research, 43(7):963-973 (2010). [cited by applicant]
Jiménez, et al., “Glucose sensor based on an amperometric microelectrode with a photopolymerizable enzyme membrane”, Sensors and Actuators B, 26-27:421-424 (1995). [cited by applicant]
Johnson, et al., “In Vivo evaluation of an electroenzymatic glucose sensor implanted in subcutaneous tissue”, Biosensors & Bioelectronics, 7:709-714 (1992). [cited by applicant]
Johnson, et al., “Reduction of Electrooxidizable Interferent Effects: Optimization of the Applied Potential for Amperometric Glucose Sensors”, Electroanalysis, 6:321-326 (1994). [cited by applicant]
Koudelka, et al., “In-vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors”, Biosensors & Bioelectronics, 6:31-36 (1991). [cited by applicant]
Kovatchev, et al., “Evaluating the Accuracy of Continuous Glucose-Monitoring Sensors”, Diabetes Care, 27(8):1922-1928 (2004). [cited by applicant]
Lodwig, et al., “Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria”, Diabetes Technology & Therapeutics, 5(4):573-587 (2003). [cited by applicant]
Moatti-Sirat, et al., “Evaluating in vitro and in vivo the interference of ascorbate and acetaminophen on glucose detection by a needle-type glucose sensor”, Biosensors and Bioelectronics, 7(5):345-352 (1992). [cited by applicant]
Nishida, et al., “Development of a ferrocene-mediated needle-type glucose sensor covered with newly designed biocompatible membrane, 2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate”, Medical Progress th… [cited by applicant]
Original Premarket Approval Application, FreeStyle Navigator Continuous Glucose Monitoring System, Section VII: Manufacturing Section Steven Label Sensor Sheet Validation Plan, vol. 28 of 31, TheraSense, Inc., 61 pages … [cited by applicant]
Poitout, et al., “Calibration in dogs of a subcutaneous miniaturized glucose sensor using a glucose meter for blood glucose determination”, Biosensors & Bioelectronics 7:587-592 (1992). [cited by applicant]
Premarket Approval Application Amendment, FreeStyle Navigator Continuous Glucose Monitoring System, vol. 2 of 39, Section III, Device Description, Abbott Diabetes Care, Inc., 89 pages (2006). [cited by applicant]
Rebrin, et al., “Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring”, American Journal of Physiology-Endocrinology and Metabolism, 277(3):E561-E571 (1999). [cited by applicant]
Related European Patent Application No. 18769490.6, Examination Report mailed May 3, 2022. [cited by applicant]
Related European Patent Application No. 18769490.6, Examination Report mailed Oct. 7, 2022. [cited by applicant]
Rhodes, et al., “Prediction of Pocket-Portable and Implantable Glucose Enzyme Electrode Performance from Combined Species Permeability and Digital Simulation Analysis”, Analytical Chemistry, 66(9):1520-1529 (1994). [cited by applicant]
Sakakida, et al., “Ferrocene-mediated needle-type glucose sensor covered with newly designed biocompatible membrane”, Sensors and Actuators B, 13-14:319-322 (1993). [cited by applicant]
Schmidtke, et al., “Accuracy of the One-Point in Vivo Calibration of ”Wired“ Glucose Oxidase Electrodes Implanted in Jugular Veins of Rats in Periods of Rapid Rise and Decline of the Glucose Concentration”, Anal. Chem.,… [cited by applicant]
The CGM Resource Center References/Bibliography, 14 pages (2011). [cited by applicant]
Tierney, et al., “Effect of Acetaminophen on the Accuracy of Glucose Measurements Obtained with the GlucoWatch Biographer”, Diabetes Technology & Therapeutics, 2(2):199-207 (2000). [cited by applicant]
Turner, et al., Biosensors: Fundamentals and Applications, Oxford University Press, New York, 786 pages (1987). [cited by applicant]
United States Securities and Exchange Commission, Form 10-K, DexCom, Inc., 59 pages (2005). [cited by applicant]
United States Securities and Exchange Commission, Form S-1, DexCom, Inc. 309 pages (2005). [cited by applicant]
Velho, et al., “Strategies for Calibrating a Subcutaneous Glucose Sensor”, Biomed. Biochim. Acta, vol. 48, pp. 957-964 (1989). [cited by applicant]
Ward, et al., “A new amperometric glucose microsensor: in vitro and short-term in vivo evaluation”, Biosensors & Bioelectronics, 17:181-189 (2002). [cited by applicant]
Wilson, et al., “Introduction to the Glucose Sensing Problem” In Vivo Glucose Sensing, Chapter 1, pp. 1-27 (2010). [cited by applicant]
Yang, et al., “Glucose Biosensors Based on Oxygen Electrode with Sandwich-Type Membranes”, Annals of Biomedical Engineering, 23:833-839 (1995). [cited by applicant]
Yang, et al., “Glucose Biosensors with Enzyme Entrapped in Polymer Coating”, Biomedical Instrumentation & Technology, 29(2):125-133 (1995). [cited by applicant]
U.S. Appl. No. 17/891,588 (US 2022/0386903 A1), filed Aug. 19, 2022 (Dec. 8, 2022). [cited by applicant]
U.S. Appl. No. 17/950,538 (US 2023/0028587 A1), filed Sep. 22, 2022 (Jan. 26, 2023). [cited by applicant]
U.S. Appl. No. 17/891,588, filed Nov. 25, 2022 Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 17/950,538, filed Jan. 23, 2023 Response to Non-Final Office Action. [cited by applicant]
U.S. Appl. No. 17/950,538, filed Dec. 21, 2022 Non-Final Office Action. [cited by applicant]
COHRlastic Silicone Rubber Products, Saint-Gobain Performance Plastics, 7 pages (2022). [cited by applicant]
Elastosil® RT 602, RTV-2 Silicone Encapsulant, Version 3.00, Wacker Silicones, 2 pages (2004). [cited by applicant]
Elastosil® RTV-1 Silicone Rubber, Wacker Silicone, 16 pages (2001). [cited by applicant]
Exhibit 3, GE Silicones—Master Grade, General Electric Company, 2 pages (2003). [cited by applicant]
Exhibit 4, Elastosil® LR 3162 A, B, Version 3.00, Wacker Silicones, 3 pages (2004). [cited by applicant]
Fujipoly® New High Performance Silver ZEBRA®Connector, Fujipoly Data Sheet No. FPDS 01-34 / Version 2, 7 pages (2002). [cited by applicant]
U.S. Appl. No. 60/614,683, 447 pages (2004). [cited by applicant]
SILASTIC® 94-595, Product Information Liquid Silicone Rubber, Dow Corning, 4 pages (2002). [cited by applicant]
Z-Carbon LCD Connector, Z-Axis Connector Company, 2 pages (2004). [cited by applicant]
Chen et al., “A novel fault-tolerant sensor system for sensor drift compensation”, Sensors and Actuators, A 147:623-632 (2008). [cited by applicant]
Kalivas et al., “Compensation for Drift and Interferences in Multicomponent Analysis”, Laboratory for Chemometrics, Department of Chemistry, University of Washington, 38 pages (1982). [cited by applicant]
Thévenot et al., “Electrochemical Biosensors: Recommended Definitions and Classification (Technical Report)”, Pure Appl. Chem. 71(12):2333-2348 (1999). [cited by applicant]
U.S. Appl. No. 12/842,013 Office Action mailed Aug. 26, 2015. [cited by applicant]
U.S. Appl. No. 12/842,013 Office Action mailed Mar. 23, 2016. [cited by applicant]
U.S. Appl. No. 12/842,013 Office Action mailed Nov. 6, 2014. [cited by applicant]
Walt et al., “The chemistry of enzyme and protein immobilization with glutaraldehyde”, Trends in Analytical Chemistry, 13(10):425-430 (1994). [cited by applicant]
“Within Definition & Meaning” retrieved from “https://www.dictionary.com/browse/within” on Sep. 9, 2022, 5 pages. [cited by applicant]
Zhang, “Investigations of potentially implantable glucose sensors”, University of Kansas, 24 pages (1991). [cited by applicant]
Extended European Search Report dated Apr. 28, 2023 corresponding to European Patent Application No. EP 23 16 3721. [cited by applicant]
U.S. Appl. No. 60/687,199, filed Jun. 2, 2005, Ward, et al. [cited by applicant]
U.S. Appl. No. 61/155,889, filed Feb. 26, 2009, Hoss, et al. [cited by applicant]
Abel, et al., “Biosensors for in vivo glucose measurement: can we cross the experimental stage”, Biosensors and Bioelectronics, 17:1059-1070 (2002). [cited by applicant]
Atanasov, et al., “Implantation of a refillable glucose monitoring-telemetry device”, Biosensors & Bioelectronics, 12(7):669-680 (1997). [cited by applicant]
Bindra, “Development of potentially implantable glucose sensors”, The University of Arizona, 227 pages (1990). [cited by applicant]
Choleau, et al., “Calibration of a subcutaneous amperometric glucose sensor implanted for 7 days in diabetic patients Part 2. Superiority of the one-point calibration method”, Biosensors and Bioelectronics, 17:647-654 (… [cited by applicant]
Frost, et al., “Implantable chemical sensors for real-time clinical monitoring: progress and challenges”, Current Opinion in Chemical Biology, 6:633-641 (2002). [cited by applicant]
Guardian®REAL-Time, Continuous Glucose Monitoring System, User Guide, Medtronic MiniMed, Inc., 184 pages (2006). [cited by applicant]
Kerner, et al., The function of a hydrogen peroxide-detecting electroenzymatic glucose electrode is markedly impaired in human sub-cutaneous tissue and plasma, Biosensors & Bioelectronics, 8:473-482 (1993). [cited by applicant]
Koschinsky, et al., “Sensors for glucose monitoring: technical and clinical aspects”, Diabetes/Metabolism Research and Reviews, 17:113-123 (2001). [cited by applicant]
Koschwanez, et al., “In vitro, in vivo and post explantation testing of glucose-detecting biosensors: Current methods and recommendations”, Biomaterials, 28:3687-3703 (2007). [cited by applicant]
Moussy, et al. “Performance of Subcutaneously Implanted Needle-Type Glucose Sensors Employing a Novel Trilayer Coating”, Anal. Chem., 65:2072-2077 (1993). [cited by applicant]
Pickup, et al., “In vivo glucose sensing for diabetes management: progress towards non-invasive monitoring”, BMJ, 319, pp. 1-4 (1999). [cited by applicant]
Pickup, et al., “Responses and calibration of amperometric glucose sensors implanted in the subcutaneous tissue of man”, Acta Diabetol, 30:143-148 (1993). [cited by applicant]
Ward, et al., “Rise in background current over time in a subcutaneous glucose sensor in the rabbit: relevance to calibration and accuracy”, Biosensors & Bioelectronics, 15:53-61 (2000). [cited by applicant]
Wilson, et al., “Biosensors for real-time in vivo measurements”, Biosensors and Bioelectronics, 20:2388-2403 (2005). [cited by applicant]
Wisniewski, et al., “Analyte flux through chronically implanted subcutaneous polyamide membranes differs in humans and rats”, Am J Physiol Endocrinol Metab, 282:E1316-E1323 (2002). [cited by applicant]
U.S. Appl. No. 17/950,538, dated Jul. 3, 2023 Notice of Allowance. [cited by applicant]
“Abbott Receives CE Mark for Freestyle® Libre, A Revolutionary Glucose Monitoring System for People with Diabetes,” 8 pages (2023). [cited by applicant]
“DexCom (DXCM) Q1 2018 Results—Earnings Call Transcript” retrieved from https://seekingalpha.com/article/4168949-dexcom-dxcm-q1-2018-results-earnings-call-transcript on May 2, 2018, 4 pages. [cited by applicant]
“FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices,” FDA News Release, retrieved from https://www.fda.gov/news-events/press-announcements/fda-a… [cited by applicant]
ATTD Program, 4 pages (2009). [cited by applicant]
Cambridge Dictionary of American English, 3 pages (2000)—Recess. [cited by applicant]
Dexcom (DXCM) Company Profile, 2017 /Q4 Earnings call transcript, 12 pages (2017). [cited by applicant]
Dexcom G6 Continuous Glucose Monitoring System User Guide, 7 pages (2020). [cited by applicant]
Dexcomg6, Continuous Glucose Monitoring System, User Guide, 22 pages (2020). [cited by applicant]
Dexcomg6, Start Here, Set up, Dexcom G6 Continuous Glucose Monitoring (CGM) System (G6), 8 pages (2019). [cited by applicant]
DexcomG6, Using Your G6, 7 pages (2020). [cited by applicant]
Drawing Sheets for U.S. Pat. No. 10,973,443 issued Apr. 13, 2021, 2 pages. [cited by applicant]
Email communication from Sophie Hood, Jan. 24, 2023, 6 pages. [cited by applicant]
Excerpts from Expert Report of Catharine M. Lawton—Ex. 36, Spruce Point Capital Mangement, Does Dexcom Really Have A Future If It Can't Match Abbott's Scale? 2 pages, Mar. 21, 2019. [cited by applicant]
Excerpts from U.S. Pat. No. 10,827,954, issued on Nov. 10, 2020, 7 pages. [cited by applicant]
Excerpts from U.S. Pat. No. 10,973,443, issued on Apr. 13, 2021, 22 pages. [cited by applicant]
Hall, An Interview with Kevin Sayer, President and CEO of Dexcom About The New Dexcom G6, College Diabetes Network, 6 pages (2021). [cited by applicant]
Hoss et al., “Continuous glucose monitoring in the tissue: Do we really need to calibrate in-vivo?,” Diabetes Technology & Therapeutics, vol. 11, No. 2, 23 pages (2009). [cited by applicant]
Hoss, et al., “Continuous Glucose Monitoring in Subcutaneous Tissue Using Factory-Calibrated Sensors: A Pilot Study”, Diabetes Technology & Therapeutics, 12(8):591-597 (2010). [cited by applicant]
IEEE 100, The Authoritative Dictionary of IEEE Standards Terms, 7 [cited by applicant]
Interview with Dexcom CEO, Dexcom CEO Kevin Sayer Explains G6, Written By: Michelle Boise, 9 pages (2018). [cited by applicant]
Joint Declaration of Funderburk, et al. for U.S. Appl. No. 15/963,828, 11 pages (2020). [cited by applicant]
Letter from the Department of Health & Human Service, Food and Drug Administration to Abbott Diabetes Care, Inc. dated Mar. 12, 2008, regarding the Premarket Approval Application (PMA) for the FreeStyle Navigator Contin… [cited by applicant]
Merriam-Webster's Collegiate Dictionary, 10 [cited by applicant]
Merriam-Webster's Collegiate Dictionary, 10 [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 14/884,622 dated Jun. 13, 2018, 7 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/030,030 dated Dec. 17, 2020, 7 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/963,828 dated Mar. 3, 2021, 32 pages. [cited by applicant]
Omnipod image, Exhibit 182, 2 pages, Sep. 22, 2022. [cited by applicant]
Response to Non-Final Office Action for U.S. Appl. No. 15/963,828, filed Dec. 8, 2020, 17 pages. [cited by applicant]
Response to Restriction Requirement for U.S. Appl. No. 14/884,622, filed Apr. 5, 2018, 15 pages. [cited by applicant]
S&P Global Market Intelligence “DexCom, Inc. NasdaqGS:DXCM, Company Conference Presentation,” 17 pages (2021). [cited by applicant]
S&P Global Market Intelligence “DexCom, Inc. NasdaqGS:DXCM, Company Conference Presentation,” 10 pages (2020). [cited by applicant]
S&P Global Market Intelligence “DexCom, Inc. NasdaqGS:DXCM, Company Conference Presentation,” 11 pages (2019). [cited by applicant]
Sayer, CGMS Changing Diabetes Management: Kevin Sayer, DIC Interview Transcript, Featuring Steve Freed, 11 pages (2019). [cited by applicant]
Sonix, Dexcom CEO- Prime Position in Our Market—Mad Money—CNBC.mp4, 4 pages (2023). [cited by applicant]
Tegnestedt, et al., “Levels and sources of sound in the intensive care unit—an observational study of three room types”, Acta Anaesthesiologica Scandinavica, pp. 1-10 (2013). [cited by applicant]
The Chambers Dictionary, 4 pages (1998)—Retract. [cited by applicant]
The MiniMed Paradigm® REAL-Time Insulin Pump and Continuous Glucose Monitoring System, Insulin Pump User Guide, Paradigm® 522 and 722 Insulin Pumps, Medtronic MiniMed, Inc., 25 pages (2008). [cited by applicant]
The New Oxford American Dictionary, 3 pages (2001)—Retract. [cited by applicant]
The New Penguin English Dictionary, Penguin Books, 4 pages (2000)—Recess. [cited by applicant]
U.S. Food & Drug Administration, “Deciding When to Submit a 510(k) for a Change to an Existing Device, Guidance for Industry and Food and Drug Administration Staff,” 78 pages (2017). [cited by applicant]
U.S. Food & Drug Administration, “Deciding When to Submit a 510(k) for a Software Change to an Existing Device, Guidance for Industry and Food and Drug Administration Staff,” 32 pages (2017). [cited by applicant]
U.S. Pat. No. 10,827,954 issued Nov. 10, 2020, Excerpts from File Wrapper, 7 pages. [cited by applicant]
Watkin, “An Introduction to Flash Glucose Monitoring,” 16 pages (2013). [cited by applicant]
Webster's New College Dictionary, 2 pages (2001) - Alcove. [cited by applicant]
Webster's Third New International Dictionary, 5 pages (1993)—Retract. [cited by applicant]